A new study has mapped the effects of ketamine on the brain, finding that repeated use over extended periods creates...
A systematic review of medical research has shown that ketamine and esketamine show no adverse cognitive effects in treatment-resistant depression.
Salvinorin A, derived from the plant Salvia divinorum, is to be researched as a treatment for mental health conditions.
Beckley Psytech has raised £58m from investors and supporters in an oversubscribed Series B financing round.
A new review has suggested mixing classic psychedelics with lithium could pose a heightened risk of seizures.
Awakn Life Sciences Corp.
Wesana Health is to undertake a functional animal study to determine the effect of psilocybin treatment on Traumatic Brain Injury (TBI), and anxiety and depression.
A team of researchers has identified novel mechanistic insights on how ketamine exerts an anti-depression effect, raising the hope of finding new treatment options for the...
An international patent application has been filed by Mindset Pharma Inc.
UK scientists are to research the potential of psilocybin to boost the effects of talking therapies for people with an end-of-life diagnosis.
The UK not-for-profit organisation, Heroic Hearts, is to undertake groundbreaking research exploring the potential of psilocybin for treating traumatic brain injury in veterans.
Psychedelics company Silo Wellness has today announced a UK distribution partnership for its Marley One functional mushroom products.
Awakn Life Sciences has announced the opening of its second psychedelic therapy clinic that will be located in London.